Eli Lilly & Co (LLY) Stock Forecast & Price Target

Compare

21,188 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LLY Analyst Ratings

Strong Buy

18 Buy

3 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

$1,261.00

▲(27.33% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $1,261.00 with a high forecast of $1,500.00 and a low forecast of $950.00. The average price target represents a 27.33% change from the last price of $990.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"729":"$729","922":"$922","1115":"$1,115","1308":"$1,308","1501":"$1,501"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1261,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.26K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":950,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$950.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[729,922,1115,1308,1501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1017.97,1055.0492307692307,1092.1284615384616,1129.2076923076922,1166.2869230769231,1203.3661538461538,1240.4453846153847,1277.5246153846153,1314.6038461538462,1351.683076923077,1388.7623076923078,1425.8415384615384,1462.920769230769,{"y":1500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1017.97,1036.6646153846154,1055.3592307692309,1074.0538461538463,1092.7484615384615,1111.443076923077,1130.1376923076923,1148.8323076923077,1167.5269230769231,1186.2215384615386,1204.916153846154,1223.6107692307692,1242.3053846153846,{"y":1261,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1017.97,1012.7415384615385,1007.5130769230769,1002.2846153846154,997.0561538461538,991.8276923076924,986.5992307692308,981.3707692307693,976.1423076923077,970.9138461538462,965.6853846153846,960.4569230769231,955.2284615384615,{"y":950,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":913.863,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":799.311,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":788.263,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":743.149,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":771.776,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":758.278,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 79,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":730.286,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":822.836,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":860.159,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1056.127,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1072.889,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1042.39,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1017.97,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,500

Average Price Target$1,261

Lowest Price Target$950.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emily Field

Barclays

$1,350

Buy

36.32%

Upside

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Ardent Health Partners, Inc. (NYSE: ARDT) and Caribou Biosciences (NASDAQ: CRBU)

Mohit Bansal

Wells Fargo

$1,280

Buy

29.25%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (NASDAQ: TLSI), Metagenomi, Inc. (NASDAQ: MGX) and Eli Lilly & Co (NYSE: LLY)

Chris Schott

J.P. Morgan

$1,300

Buy

31.27%

Upside

Reiterated

03/05/26

J.P. Morgan Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Michael Yee

UBS

$1,250

Buy

26.22%

Upside

Reiterated

03/05/26

Eli Lilly: Amylin Leadership and Pipeline Upside Support Buy Rating in Next‑Generation Obesity Therapies

Courtney Breen

Bernstein

$1,300

Buy

31.27%

Upside

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Radnet (NASDAQ: RDNT), Amgen (NASDAQ: AMGN) and Eli Lilly & Co (NYSE: LLY)

Geoff Meacham

Citi

$1,500

Buy

51.46%

Upside

Reiterated

02/26/26

Citi Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Jason Gerberry

Bank of America Securities

$1,293

Buy

30.56%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Bausch Health Companies (NYSE: BHC)

Trung Huynh

RBC Capital

$1,250

Buy

26.22%

Upside

Initiated

02/24/26

Eli Lilly initiated with an Outperform at RBC CapitalEli Lilly initiated with an Outperform at RBC Capital

Evan Seigerman

BMO Capital

―

Buy

―

Reiterated

02/23/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Asad Haider

Goldman Sachs

$1,260

Buy

27.23%

Upside

Reiterated

02/23/26

Eli Lilly: Conservative 2026 Guide, Diversified Pipeline, and Capital Flexibility Underscore Buy Rating Amid Obesity Leadership

Srikripa Devarakonda

Truist Financial

$1,182→$1,281

Buy

29.35%

Upside

Reiterated

02/05/26

Analysts Are Bullish on Top Healthcare Stocks: Illumina (ILMN), Veeva Systems (VEEV)

Louise Chen

Scotiabank

$1,165→$1,300

Buy

31.27%

Upside

Reiterated

02/05/26

Eli Lilly price target raised to $1,300 from $1,165 at ScotiabankEli Lilly price target raised to $1,300 from $1,165 at Scotiabank

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

02/05/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Eli Lilly & Co (NYSE: LLY)

Kerry Holford

Berenberg Bank

$950

Hold

-4.07%

Downside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Maravai Lifesciences Holdings (NASDAQ: MRVI)

Seamus Fernandez

Guggenheim

$1,163→$1,161

Buy

17.23%

Upside

Reiterated

01/20/26

Eli Lilly price target lowered to $1,161 from $1,163 at GuggenheimEli Lilly price target lowered to $1,161 from $1,163 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emily Field

Barclays

$1,350

Buy

36.32%

Upside

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Ardent Health Partners, Inc. (NYSE: ARDT) and Caribou Biosciences (NASDAQ: CRBU)

Mohit Bansal

Wells Fargo

$1,280

Buy

29.25%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (NASDAQ: TLSI), Metagenomi, Inc. (NASDAQ: MGX) and Eli Lilly & Co (NYSE: LLY)

Chris Schott

J.P. Morgan

$1,300

Buy

31.27%

Upside

Reiterated

03/05/26

J.P. Morgan Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Michael Yee

UBS

$1,250

Buy

26.22%

Upside

Reiterated

03/05/26

Eli Lilly: Amylin Leadership and Pipeline Upside Support Buy Rating in Next‑Generation Obesity Therapies

Courtney Breen

Bernstein

$1,300

Buy

31.27%

Upside

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Radnet (NASDAQ: RDNT), Amgen (NASDAQ: AMGN) and Eli Lilly & Co (NYSE: LLY)

Geoff Meacham

Citi

$1,500

Buy

51.46%

Upside

Reiterated

02/26/26

Citi Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Jason Gerberry

Bank of America Securities

$1,293

Buy

30.56%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Bausch Health Companies (NYSE: BHC)

Trung Huynh

RBC Capital

$1,250

Buy

26.22%

Upside

Initiated

02/24/26

Eli Lilly initiated with an Outperform at RBC CapitalEli Lilly initiated with an Outperform at RBC Capital

Evan Seigerman

BMO Capital

―

Buy

―

Reiterated

02/23/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Asad Haider

Goldman Sachs

$1,260

Buy

27.23%

Upside

Reiterated

02/23/26

Eli Lilly: Conservative 2026 Guide, Diversified Pipeline, and Capital Flexibility Underscore Buy Rating Amid Obesity Leadership

Srikripa Devarakonda

Truist Financial

$1,182→$1,281

Buy

29.35%

Upside

Reiterated

02/05/26

Analysts Are Bullish on Top Healthcare Stocks: Illumina (ILMN), Veeva Systems (VEEV)

Louise Chen

Scotiabank

$1,165→$1,300

Buy

31.27%

Upside

Reiterated

02/05/26

Eli Lilly price target raised to $1,300 from $1,165 at ScotiabankEli Lilly price target raised to $1,300 from $1,165 at Scotiabank

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

02/05/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Eli Lilly & Co (NYSE: LLY)

Kerry Holford

Berenberg Bank

$950

Hold

-4.07%

Downside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Maravai Lifesciences Holdings (NASDAQ: MRVI)

Seamus Fernandez

Guggenheim

$1,163→$1,161

Buy

17.23%

Upside

Reiterated

01/20/26

Eli Lilly price target lowered to $1,161 from $1,163 at GuggenheimEli Lilly price target lowered to $1,161 from $1,163 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months

xxx

Success Rate

26/35 ratings generated profit

Average Return

+8.33%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 74.29% of your transactions generating a profit, with an average return of +8.33% per trade.

1 Year

Geoff MeachamCiti

Success Rate

40/44 ratings generated profit

Average Return

+38.36%

a rating ―

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +38.36% per trade.

2 Years

xxx

Success Rate

39/39 ratings generated profit

Average Return

+72.69%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +72.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LLY has received 40 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,261.00.

Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is $7.25 with a range of $3.63 to $8.56. The previous quarter’s EPS was $7.54. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is $17.61B with a range of $13.64B to $19.38B. The previous quarter’s sales results were $19.29B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Stock Forecast FAQ

What is LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,261.00.

What is LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly & Co has 27.33% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LLY a Buy, Sell or Hold?

Eli Lilly & Co has a consensus rating of Strong Buy which is based on 18 buy ratings, 3 hold ratings and 0 sell ratings.

What is Eli Lilly & Co’s price target?

The average price target for Eli Lilly & Co is 1,261.00. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,500.00 ,the lowest forecast is $950.00. The average price target represents 27.33% Increase from the current price of $990.33.

What do analysts say about Eli Lilly & Co?

Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of LLY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Eli Lilly & Co (LLY) Stock Forecast & Price Target

LLY Analyst Ratings

LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

LLY Analyst Recommendation Trends

LLY Financial Forecast

LLY Earnings Forecast

LLY Sales Forecast

LLY Stock Forecast FAQ

Detailed List of Analyst Forecasts